RAMP has the potential to improve healthcare worldwide: the case of Pioglitazone

Updated: Jul 29, 2018

Pioglitazone is the active substance of a generic drug used against type 2 diabetes. In 2008, it was the 10th best-selling drug in the USA.

There are many drugs against type 2 diabetes. RAMP allows to compare efficacy and safety of different drugs, among other parameters. This is how our team noticed that Pioglitazone was 1000 times more likely to induce a fatal condition than other more recent drugs.

Prescribing other therapies than Pioglitazone might therefore be relevant for many patients. RAMP allows medical doctors to see it in the blink of an eye, and enables them to choose the best therapy there is for their patients.


Henisaja GmbH


Kastanienallee 61

10119 Berlin


Chief Executive Officer:  Helene Schönewolf

+49 (0) 30 31 98 08 52​

Registered at the local court Berlin Charlottenburg HRB 167143 B

VAT: DE299921795

Follow us


Copyright 2020 | RAMPmedical